$TARS (TARSUS PHARMACEUTICALS) — 8-K: Tarsus completes Alkeus acquisition, adding Phase 3 Stargardt asset ALK-001

Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, gaining worldwide rights to gildeuretinol (ALK-001). ALK-001 is a Phase 3 oral investigational medicine for Stargardt disease, which has no FDA-approved therapy and affects as many as 86,000 people in the United States. Topline data from the global NORTHSTAR Phase 3 trial are anticipated in 2029.

Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, gaining worldwide rights to gildeuretinol (ALK-001). ALK-001 is a Phase 3 oral investigational medicine